## MAX-40279 hemiadipate

Cat. No.:	HY-145723C	
CAS No.:	2388506-44-1	
Molecular Formula:	C <sub>22</sub> H <sub>23</sub> FN <sub>6</sub> OS. <sub>1/2</sub> C <sub>6</sub> H <sub>10</sub> O <sub>4</sub>	HN
Molecular Weight:	584.66	
Target:	FLT3; FGFR	
Pathway:	Protein Tyrosine Kinase/RTK	1/2 HO
Storage:	-20°C, sealed storage, away from moisture	Ö
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

**Product** Data Sheet

## SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (42.76 mM; ultrasonic and warming and heat to 60°C) DMF : 10 mg/mL (17.10 mM; ultrasonic and warming and heat to 60°C)					
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	
		1 mM	1.7104 mL	8.5520 mL	17.1040 mL	
		5 mM	0.3421 mL	1.7104 mL	3.4208 mL	
		10 mM	0.1710 mL	0.8552 mL	1.7104 mL	
	Please refer to the sol	ubility information to select the app	propriate solvent.			
In Vivo	<ol> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.08 mg/mL (3.56 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (3.56 mM); Clear solution</li> </ol>					

BIOLOGICAL ACTIVITY				
Description	MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032) <sup>[1]</sup> .			
IC <sub>50</sub> & Target	FLT3 and FGFR <sup>[1]</sup>			

## REFERENCES

[1]. Yuguang Wang, et al. Novel Therapeutic Methods. Patent WO2021180032A1.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA